title: Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
abstract: The synchronous existence of lung cancer and gastrointestinal stromal tumors (GIST) is considered to be extremely rare. To the best of our knowledge, this is the first report about the treatment of lung cancer and GIST with two kinds of molecular targeting drugs. An 83-year-old woman with a rectal GIST, which carried a c-kit mutation, and pulmonary adenocarcinoma, which exhibited an epidermal growth factor receptor (EGFR) mutation, was treated alternately with imatinib and erlotinib. Good control over both diseases was achieved for two years. The present case is not only of interest due to the rare co-occurrence of GIST and lung cancer, but also because it involved two tumors carrying different gene mutations, and both tumors were brought under control using different molecular targeting drugs.
authors.affiliation: Department of Surgery, Tokushima Municipal Hospital.
authors.forename: Takanori
authors.initials: T
authors.lastname: Miyoshi
authors.forename: Riho
authors.initials: R
authors.lastname: Mori
authors.forename: Sachiko
authors.initials: S
authors.lastname: Amano
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sumitomo
authors.forename: Mariko
authors.initials: M
authors.lastname: Aoyama
authors.forename: Seiya
authors.initials: S
authors.lastname: Inoue
authors.forename: Naoki
authors.initials: N
authors.lastname: Hino
authors.forename: Daisuke
authors.initials: D
authors.lastname: Wada
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D018773:Genes, erbB-1; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D009378:Neoplasms, Multiple Primary / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D012004:Rectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000068877:Imatinib Mesylate; D000069347:Erlotinib Hydrochloride; D019009:Proto-Oncogene Proteins c-kit